Sponsors and contract research organizations (CROs) have depended on each other for more than 30 years to bring therapies to market. But the relationship has grown more complex over time, and the pressure on both sides has never been higher.

The numbers tell part of the story: The global CRO market was valued at $84.6 billion in 2025 and is projected to grow at a compound annual growth rate of 8.3% through 2030. Tufts Center for the Study of Drug Development reports that sponsors now outsource 70% to 80% of trial activities, depending on phase and function. These statistics illustrate just how embedded outsourcing has become in modern clinical development.

And yet, shared frustrations are common. Sponsors often feel they’re paying for expertise and getting inconsistency instead, CROs feel squeezed on price and held to expectations that were never realistic, and study teams sit in the middle, trying to protect quality while navigating pressure from both sides. These aren’t new problems, but understanding what drives them can help strengthen relationships from start to finish. 

This white paper explores some of the common reasons for this disconnect and provides guidance for strengthening CRO-sponsor relationships.

Regulatory accountability doesn’t transfer

One of the clearest drivers of poor CRO-sponsor relationships starts with the regulatory framework itself. Under ICH E6(R2), sponsors may transfer trial-related duties to a CRO, but they retain ultimate responsibility for trial quality and data integrity. The FDA takes the same position: delegating tasks doesn’t remove the sponsor’s oversight obligations. That’s a critical distinction; outsourcing changes who performs the work, but it doesn’t change who owns the outcome.

When oversight is reactive rather than ongoing and structured, accountability gaps widen. Sponsors may assume the CRO has operational control, while CROs may assume sponsors understand the contractual constraints, and neither assumption holds up under pressure. This is usually where the misalignment starts.

The problem with procurement-driven pricing

Another point of friction is pricing. Regulatory accountability may rest with the sponsor, but financial reality shapes how it plays out in practice.

Most sponsors have procurement functions. Clinical trials are expensive, and fiscal discipline matters. The challenge is when rigid fixed-bid structures are applied to inherently variable studies.

When pricing pressure intensifies, CROs respond in predictable ways: narrowing operational assumptions, staffing tightly, and reducing contingency buffers. Competing on price to win the award becomes part of the calculus.

Margin compression doesn’t automatically compromise quality, but it does reduce flexibility. Once a study begins, real-world conditions rarely match what was scoped. Protocol amendments, enrollment delays, evolving monitoring requirements, and growing data volumes all push the original financial model past its limits, and change orders become inevitable.

When contract conversations replace operational ones

Those change orders tend to reshape the CRO-sponsor relationship itself. Sponsors often read them as evidence that the study was underbid, while CROs view them as reasonable adjustments to the expanded scope. Without alignment on how to handle that tension, the relationship suffers, and so does the work.

When financial discussions start crowding out operational conversations, the whole study feels it. Routine calls shift from problem-solving to contract negotiation, monitoring oversight becomes inconsistent, and timelines slip. Site performance, data quality, and compliance can also take a hit, and over time, that adds up to slower execution, higher costs, and delayed patient access to therapies.

Workforce pressure makes everything harder

These dynamics don’t play out in a vacuum. Behind every contract are clinical teams managing complex, high-stakes workloads. CRAs remain in high demand, and the Association of Clinical Research Professionals has documented ongoing workforce strain and elevated workload concerns across the field.

Turnover disrupts monitoring continuity and the institutional knowledge that keeps studies running well. Each staffing transition means retraining, site relationship resets, and lost context for ongoing work. Sponsors experience this as inconsistent communication and variable oversight, and CROs face resourcing pressure in an already competitive hiring environment.

Those challenges worsen when timelines are compressed, and staffing models have little room for redundancy. Consider that Protocol complexity has grown significantly over the last two decades, with the IQVIA Institute noting that today’s studies carry more endpoints, procedures, and data requirements than ever before. That complexity demands greater coordination, which can create even more friction.

Patterns worth recognizing

Taken together, these regulatory, financial, contractual, and workforce pressures tend to produce the same breakdown patterns across therapeutic areas and study phases. Some of those patterns include:

1. Budget assumptions that don’t reflect real-world variability. Fixed bids built on optimistic assumptions set both sides up for conflict the moment conditions change, and in clinical research, conditions always change.
2. Limited early collaboration during feasibility and protocol planning. When CROs are brought in after key decisions have already been made, they’re left executing a plan they had no hand in building, which makes it harder to flag risks before they become problems.
3. Opacity around staffing allocation. Sponsors rarely have full visibility into how their study is being resourced, and that lack of transparency makes it difficult to assess whether the team assigned to their program has the bandwidth and experience to deliver.
4. Reactive governance rather than shared, proactive oversight. Governance structures that only activate when something goes wrong are too slow for the pace of modern trials. By the time an issue surfaces formally, the damage is usually already done.
5. Partnership language that isn’t backed by operational structure. Calling a vendor relationship a “partnership” doesn’t make it one. Without shared decision rights, aligned incentives, and defined escalation pathways, the language is just window dressing.

What stronger partnerships look like

The good news is that the same patterns that predict breakdown can also point to what works. No two sponsor-CRO relationships are identical, but the ones that hold up under pressure tend to share the same characteristics:

1. Clear, agreed-upon delineation of regulatory responsibility. Both sides need to know exactly where sponsor oversight ends and CRO execution begins. Any ambiguity here can create compliance risk. 
2. Budgeting tied to realistic operational assumptions. A bid that wins on price but can’t survive first contact with the protocol isn’t a win for anyone. Building in realistic contingencies upfront is less painful than renegotiating mid-study.
3. Early CRO involvement in study design and feasibility. CROs that help shape the protocol are better positioned to execute it. Bringing them in after key decisions are made wastes one of the most valuable things they have to offer.
4. Transparent staffing plans with defined escalation pathways. Sponsors should know who is working on their study, at what capacity, and what happens when that changes. Opacity around resourcing is one of the fastest ways to erode trust.
5. Joint governance with clear decision rights on both sides. Governance only works when both parties know who owns which decisions and how disputes get resolved. Without that structure, every disagreement becomes a negotiation.

Candid conversations about constraints, raised early rather than after a problem surfaces, can help prevent most conflict. Setting honest expectations during contracting reduces renegotiation during execution and keeps both sides focused on the trial, instead of the terms.

FSP as an alternative structure

Even with these tips, better relationship management can only go so far when the underlying structure is working against you. While the traditional full-service model remains the right fit for many programs, particularly those requiring broad operational delegation across multiple sites, many organizations are now evaluating engagement models that offer more flexibility. The Functional Service Provider (FSP) model is one of those alternative structures.

Under the FSP model, sponsors retain strategic oversight while outsourcing defined functions rather than transferring an entire study. That approach changes several dynamics: 

• Sponsors maintain direct program visibility instead of receiving filtered updates through a full-service layer
• CRO partners contribute focused expertise within clearly defined domains
• Staffing scales in alignment with actual portfolio demands
• Institutional knowledge stays embedded within sponsor teams rather than disappearing when a CRO relationship ends.

Because FSP arrangements require strong internal infrastructure and active sponsor involvement they work best for organizations that are prepared to stay engaged rather than fully delegate. For those that are, they can address much of the misalignment that rigid fixed-bid frameworks tend to produce.

Hybrid arrangements, including strategic alliances and risk-sharing structures, are also gaining traction across the industry. The common thread is that structure influences behavior. When financial incentives align with shared program outcomes rather than narrow contractual obligations, collaboration tends to improve alongside them.

Better partnerships start before the contract is signed

The problems described throughout this piece are the predictable result of clinical trial structures that haven’t kept pace with how complex drug development has become. CRO relationships break down when incentives diverge, communication narrows, and oversight becomes reactive, and they hold together when expectations, governance, and accountability are defined clearly from the start and maintained throughout.

Outsourcing will keep expanding as trials grow more complex and specialized expertise stays in demand. The organizations that get the most out of their research will be the ones that invest in structuring their partnerships deliberately, before the work begins.

At Harbor Clinical, we work with sponsors across full-service and FSP engagements, with an emphasis on experienced teams, transparent collaboration, and governance that holds up under regulatory scrutiny. If you’re assessing how your current CRO relationships are performing, or thinking through engagement structures for upcoming programs, we’re happy to start that conversation. Request a proposal today.